| Literature DB >> 33110770 |
Waseem N Ahmed1, Chankramath S Arun2, Thanuvelil G Koshy3, Abilash Nair4, Prasanth Sankar5, Sabeer A Rasheed6, Reeja Ann7.
Abstract
INTRODUCTION: Fasting is observed as a religious custom in various forms across the globe. Among them, the Ramadan fasting is very common and widely practiced. People with diabetes observe fasting with or without obtaining medical advice. Uncontrolled diabetes appears to be a risk factor for COVID-19 infection and its poorer outcomes. Fasting during Ramadan is challenging in people with diabetes. This year, the background of COVID-19 made it difficult for both the patients and health care workers to effectively manage diabetes and its complications during Ramadan. Because of a lack of sufficient evidence, clinicians were perplexed in handling this difficult situation.Entities:
Keywords: COVID-19; India; Ramadan; diabetes; fasting; primary care physician
Year: 2020 PMID: 33110770 PMCID: PMC7586529 DOI: 10.4103/jfmpc.jfmpc_845_20
Source DB: PubMed Journal: J Family Med Prim Care ISSN: 2249-4863
Summary of the benefits of fasting[1519]
| Metabolic Benefits | Other Systemic Benefits |
|---|---|
| Reduction in plasma glucose | Increases average life expectancy and promotes psychological well-being |
| Increase in insulin sensitivity | Improves physical composition and function |
| Reduction in Low Density Lipoprotein-C, total cholesterol, and triglyceride level | Enhances cognitive functions - spatial, associative and working memory |
| Increase in High Density Lipoprotein-C level | Reduction in Atherosclerosis risk |
| Regulation of sleep pattern and ageing | |
| Reduction in blood pressure | Protects against cancer, diabetes, obesity |
| Reduction in total body weight | Delay or reverse stroke, Alzheimers disease, and Parkinsons disease |
| Reduction in waist circumference | Alleviates symptoms of asthma, multiple sclerosis, and arthritis. |
| Reduction of inflammatory marker |
LDL-C: Low Density Lipoprotein-C, HDL-C: High Density Lipoprotein-C
Risk stratification for people with Diabetes wishing to fast during Ramadan in the background of COVID -19 Pandemic[212223]
| Category | Situation |
|---|---|
| Very High | Poorly controlled patients (HbA1c >8.5%) (Average blood glucose >300 mg/dL) |
| Risk | Type 1 Diabetes mellitus |
| History of Hypoglycemic unawareness, severe or recurrent hypoglycemia, Diabetic ketoacidosis or hyperosmolar hyperglycemic coma in the last 3 months | |
| Acute illness | |
| Pre- existing DM in pregnancy or Gestational DM on insulin | |
| Immunocompromised patients [HIV, Cancer, PTB, Transplant recipients, on immunosuppressants] | |
| Associated co-morbidities like heart failure, recent myocardial infarction, hepatic failure, severe respiratory illness, CKD Stage 4 and 5] | |
| Elderly who are ill | |
| COVID-19 positive patients, or with history of contact or travel with COVID-19 positive patients. | |
| High risk | Moderately controlled patients (HbA1c 7.5-8.5%) (Average blood glucose 150-300 mg/dL) |
| Renal insufficiency- CKD stage 3 | |
| Pregnant and lactating women- controlled by diet only or metformin | |
| Living alone on multiple insulin injections | |
| Autonomic neuropathy, moderate to severe micro and microvascular complications | |
| Members living in same premises of COVID-19 positive patient | |
| Moderate risk | Patients with good glycemic control (HbA1c 7-7.5%) |
| On insulin, oral anti-diabetes agents, GLP-1 receptor agonists | |
| People living in COVID-19 hotspot areas | |
| Low risk | Well controlled patients (HbA1c <7%) |
| On lifestyle modification only or monotherapy and healthy |
GLP-1: Glucagon-Like-Peptide, CKD: Chronic kidney disease, DM : Diabetes mellitus, HIV : Human Immunodeficiency virus, PTB : Pulmonary tuberculosis. Adapted from: ADA 2020, IDF 2016, IGDR 2015, IDF-DAR Practical Guidelines, South Asian Consensus Guidelines, ICMR guidelines, South Asian Health Foundation Update
Figure 1Approach to a patient with Diabetes wishing to fast during Ramadan
Dietary recommendations for patients with diabetes during Ramadan fasting[21]
| • Calorie requirement is 1800-2200 kcal/day for men and 1500-2000 kcal/day for women |
| • Divide daily calories=Suhoor (30-40%) + Iftar (40-50%) + Snacks (10-20%) once or twice between meals if necessary |
| • Balanced diet with 45-50% carbohydrate, 20-30% protein, <35% fat (preferably mono- and polyunsaturated), fibre 20-35 gram per day |
| • Adequate protein and fat ensures satiety and reduced postprandial hyperglycemia |
| • Include low glycemic index, high fibre foods that release energy slowly before and after fasting |
| • Include adequate fruit, vegetables and salads |
| • Minimise foods that are high in saturated fats like samosas, pakoras |
| • Avoid sugary desserts |
| • Keep hydrated whenever possible by drinking water and other non-sweetened beverages |
| • Avoid caffeinated and sweetened drinks |
| • Avoid large calorie dense meal, and take smaller meals divided into two or three |
Physical activity recommendations for patients with Diabetes during Ramadan Fasting[2829]
| Situations | Recommendations |
|---|---|
| Those on lifestyle modification | Modifying frequency and intensity of physical activity. |
| Type 2 Diabetes on oral medications or insulin | Avoid exercise before Iftar. |
| Type 1 Diabetes | Personalised decision, Avoid intense exercise. |
| Preferable mode of exercise | Maintain normal daily routine, walking, stationary cycling. Perform Tarawih prayers. |
| Exercise timing (depending on work pattern during Ramadan) | Preferably 2 hours after Iftar, after night (Isha) and after midnight (Tahajud) prayers. |
Effective ways to handle social concerns[44950]
| Challenges | Solutions |
|---|---|
| Disruption of pharmaceutical supply | Secure stable stock of medication |
| Loss of access to healthcare | Virtual consultation, Volunteer help |
| Lonely, technologically challenged | Telephonic consultation |
| Fear of glycemic variation | Regular self-monitoring blood glucose |
| Offering Zakaat | Pre-packaged food and safe distancing |
| Faith-based teachings and practices | Religious leaders on digital platform |
| Conducting religious gatherings | WHO risk assessment tool |
| Ensuring safe precautions | Advocacy by religious organizations in liaison with local health authorities |
| Holding Prayers after approval | Social distancing at entry and exit points |
| Smaller, shorter and periodic prayers | |
| Face mask and handwashing facility | |
| Personal prayer rugs | |
| Usage of alcohol-based hand rub | Not forbidden as topical medication |
Summary of therapeutic titration for oral anti-diabetes agents[283444525354]
| Glucose-lowering Therapy | Recommendation during Ramadan Fasting | Recommendation during COVID-19 |
|---|---|---|
| Metformin | No dose modification required for OD and BD dose. For TID dosing, one dose after suhoor and remaining two doses together after Iftar. | Stop Metformin.in COVID-19 positive with severe symptoms, poor oral intake, risk of dehydration and AKI |
| First line glucose lowering therapy | ||
| Low risk of hypoglycemia | ||
| Insulin | Avoid Glibenclamide due to high risk of hypoglycemia | Dose reduction may be needed depending on blood sugar levels |
| Secretagogues | Glimepiride, Gliclazide can be used | |
| OD dose: take at Iftar | ||
| BD dose: Iftar dose remains the same, Suhoor dose should be halved | ||
| Repaglinide: take before meals | ||
| DPP-4 inhibitors and AGI | No dose modification required | No dose modification |
| Low risk of hypoglycaemia | ||
| SGLT-2 inhibitors | No dose modification required usually | COVID -19 with severe symptoms -stop the drug. COVID -19 with no/mild symptoms -Dose modification to be considered. |
| Low risk of hypoglycaemia | ||
| Fix stable dose 4 weeks before Ramadan | ||
| Thiazolidinediones | No dose modification required | No dose modification |
| Low risk of hypoglycaemia | ||
| Hydroxychloroquine (insufficient data) | Low risk of hypoglycemia but dose of concomitant drug needs to be reduced | Hypoglycemia risk (along with few drugs) |
OD: Once daily, BD: Twice daily, TID: Thrice daily, AKI: Acute kidney injury, DPP4: Dipeptidyl peptidase 4, AGI: Alpha Glucosidase inhibitors, SGLT-2: Sodium Glucose co-transporter-2. Adapted from: ADA 2020, IDF 2016, IGDR 2015, IDF-DAR Practical Guidelines, South Asian Consensus Guidelines.
Summary of therapeutic titration for injectable therapies[28,34,44,52]
| Glucose-lowering therapy | Recommendation during Ramadan Fasting | Recommendation during COVID-19 |
|---|---|---|
| GLP-1RA | • No dose modification required | • Dose reduction needed when poor oral intake, GI problems, dehydration, AKI, active COVID -19 |
| • Low risk of hypoglycaemia | ||
| Insulin | • High risk of hypoglycemia | • Dose reduction may be needed, depending on blood sugar levels |
| OD dose: Reduce dose by 15- 30 % and take at iftar. | • Check blood glucose regularly | |
| BD dose: Normal morning dose at Iftar | • Check ketones in Type 1 | |
| And half the evening dose at Suhoor. | Diabetes regularly | |
| • Follow “sick day rules” | ||
| OD dose- Take at iftar. | ||
| BD dose- Normal morning dose at Iftar and reduce night dose by 25-50 % and take it at Suhoor. | ||
| TID dose- Omit afternoon dose, adjust Iftar and Suhoor doses according to BG every 3 days | ||
GI: Gastrointestinal, AKI: Acute kidney injury, OD: Once daily, BD: Twice daily, TID: Thrice daily, GLP-1RA : Glucagon-like-peptide-1 receptor agonist, BG: Blood glucose Adapted from: ADA 2020, IDF 2016, IGDR 2015, IDF-DAR Practical Guidelines, South Asian Consensus Guidelines.
Recommendations for diabetes management during COVID-19[283452]
| Situation | Treatment Plan |
|---|---|
| Critically ill, hospitalized | Intravenous insulin infusion [preferably] or subcutaneous basal-bolus |
| Non- critically ill, hospitalized | Insulin subcutaneous [preferably basal-bolus regimen] |
| With dehydration or | Should Stop - Diuretics, ACEI, ARB, |
| Acute Kidney Injury | Metformin, SGLT2i. Consider Stopping if required - Sulphonylureas, GLP1RA |
| Out patientse | May need dose/medication adjustment |
| COVID-19 positive | |
| Out patients without | Continue usual medications - no dose adjustment needed |
| COVID-19 | |
| On Statins | Continue medication [Cardiovascular benefit-short and long term] |
| On Anti-Hypertensives | Continue medication [Insufficient evidence to stop the drug] |
| Therapeutic Aims | |
| Random plasma glucose 72-180 mg/dL (in-patients) and 72-144 mg/dL (out-patients) | |
| Premeal CBG 80-130 mg/dL | |
| 2-hour post meal CBG <180 mg/dL | |
| HbA1c: < 7% | |
| CGM/FGM | |
| TIR (70-180 mg/dL): >70% (> 50% in frail and elderly) | |
| Hypoglycemia (<70 mg/dL): <4% (< 1% in frail and elderly) | |
| General suggestions | |
| Adequate hydration and regular blood glucose monitoring to be ensured for all. | |
| Medical Nutrition therapy to be modified according to caloric demands during acute illness. | |
| Diabetic self-foot examination and care, watch for any other complications | |
CGM: Continuous glucose monitoring, FGM: Flash glucose monitoring, TIR: Time in range
Importance of Family Physicians in Managing Diabetes during COVID-19[5960]
| • Provide cost-effective, comprehensive, continuous and holistic medical care |
| • Available and accessible to people during crisis |
| • Promote health awareness and impart good sociocultural practices |
| • Focus on primary prevention and control of risk factors for Diabetes |
| • Prevent and manage complications associated with diabetes |
| • Handle diabetes related emergencies |
| • Resolve more and refer less - reduce unnecessary burden at tertiary centres |
| • Involve in training the paramedics |
| • Assist local health authorities in policy formulation |